Good afternoon, and welcome to the Jefferies Global Healthcare Conference in London. My name is Dennis Ding, biotech analyst here. I have the great pleasure of having Inhibikase Therapeutics here. We have the CEO, Mark Iwicki. Welcome.
Thank you very much, Dennis. Great to be here.
Before we kind of go into more about the business and some of the progress you guys have made, maybe talk a little bit high level around the company and what you guys have done this year and what you guys are looking forward to.
Yeah, this has been a super exciting year for Inhibikase. We kicked off a phase III program. We have 28 countries approved and 79 sites up and running, and that's really in the past kind of four to six months. W e're feeling great, we're achieving our internal expectations. There's been a tremendous amount of excitement from thought leaders, investigators, practicing physicians about the promise of imatinib.
Most people know that imatinib had been studied before in the IMPRES trial by Novartis and had always felt like this would be a great product to bring to the market. I think in general, too, what you're seeing is antiproliferatives are of tremendous interest. Of course, sotatercept is off to a great start in the U.S. and approved in many other countries. I think it is really opening up the market that these products alone and in combination in the future will really be the next standard of care.
Sure. Maybe talk a little bit more about PAH and just how that landscape is changing with sotatercept, and then just some of the other therapeutics that are in development and could be approved in the next few years.
It was dominated by vasodilators for 20 years, 30 years, and those products are great and they are needed and they are important, but they are limited in a way in their ability to really change the long-term course of the disease. Sotatercept, an activin trap product, is an antiproliferative agent, and our product, the kinase inhibitor IKT-001, which is going to deliver imatinib, is also an antiproliferative agent. That is really changing, I think, the framing of the disease and how it is going to be treated.
We have already seen a bit of a downstreaming of sotatercept into the more moderate populations, and I think when you talk with the thought leaders, they are most excited about getting these products used earlier and earlier in the course of the disease. I think another piece of it, and we always get asked this question, "Well, does the market need multiple antiproliferative agents?" The answer to that is unequivocally yes.
No single drug is going to be able to treat this disease. There is still going to be combination therapy used routinely. In fact, I think what we are going to see in the future is combinations of antiproliferatives used, and you will see some of the more complicated vasodilator products will be pushed to kind of last line. I think you are going to see these antiproliferative agents kind of be second-line therapy, and maybe even over time, they will be a beginning, a part of a starting regimen.
Okay. You guys are in phase III, that is enrolling, and you guys will have a number of updates in 2027, 2028, and 2029. Just remind us what those are, and maybe go into a little bit more detail around some of the safety updates that you guys will have next year.
Yeah. In 2027, what we have communicated is that we will provide what we have called a safety update, and that is going to look a lot like what other people have done during the blinded portion of a study. What we are obligated to do for a financing tranche is to have 50 patients into the study and 12 weeks worth of data. The obligation we have is just to report out that the DSMB has looked at that data and that the trial can continue, and we believe that that is probably the limit to the information it will provide. W hat it will clearly do is show that we are executing well and that the trial is on track. Then a really exciting readout for us is mid-2028. That is the Part A of our study, which is 140 patients with a primary endpoint of PVR.
That often looks like a phase II study for other development programs. For us, we call that Part A, and that will be a full data set. PVR is how it is powered in the primary endpoint. We will have six-minute walk data. We will have other secondary endpoint data, so we are really excited about that. Then the pivotal data comes in mid-2029. Think of it as first half 2027 for a safety update, study is on track and rolling nicely, mid-2028, a pretty definitive data set with PVR being a highlight there, and then mid-2029, that pivotal data that we will be able to file upon.
Our program is pretty interesting in a way because what we have done is have a Part A and a Part B, but we use the same sites. As soon as the last patient is enrolled in Part A, the next patient goes right into Part B, and that will give us two independent data sets and hopefully a really good package for filing.
For the safety update next year, 50 patients worth of data, 12 weeks of follow-up, but you also said limited disclosure. I guess help us understand what exactly the DSMB is looking, what will be communicated to you, and could you guys look at perhaps blinded PVR at that point?
Yeah, look, I guess the answer to that question is we could certainly look at everything, but because it's such a small data set, just 50 patients, in principle, 25 on drug, 25 on placebo, we're likely to just stick with what we're obligated to do. That brings in a $55 million financing for us, just to be able to have the DSMB say that there are no meaningful issues that would make them want to stop the trial and that the trial could continue. It's very fair for everyone to ask investors, analysts, you'll have more data, could you report blinded information? Of course, we will have that data, but we think we'll just stick to the requirement that we have in the financing.
Okay. Maybe I'll push on that a little bit more. Because the blinded PVR, I feel like is fairly definitive because you don't really have a placebo response on PVR . Do es the DSMB have access to patient level data? Do you have access to it even on a blinded fashion?
Of course, somewhere within the organization, but not the full management team or anything like that. We are not looking at that data day-to-day. I think the tricky part is such a small, it's only 25 patients on drug, 25 patients on a placebo. I think that's the real trick. It's only 12 weeks, it's only half the study. The study's 24 weeks, so w e're not trying to in any way like not want to disclose things, but I think we'll probably stick with a high-level disclosure at this point.
Okay. Once we're in 2028 and you guys will disclose the PVR data, I guess what should people expect? Should they look at the IMPRES data and expect something similar, or do you think that that's not the case?
No, listen, that's a great question. What we've done is we made a prodrug of imatinib that stays intact in the GI tract to get a lot of benefits, and maybe we'll talk about that. O nce it's converted in the plasma, it turns right into imatinib. We do expect to have imatinib-like efficacy. I think most people would say that a clinically meaningful difference in PVR would be like a 20% reduction in six-minute walk, maybe a 20-meter improvement. Of course, in IMPRES, it was more like a 30% reduction and a 30-meter improvement in six-minute walk. We do fully expect to be able to replicate that level of efficacy.
Okay. Can you remind us, because IMPRES was a very old study. How has the treatment paradigm changed such that patients today in a modern PAH trial, should we expect that same level of efficacy that we saw years ago from IMPRES?
It's a good question. Look, I think in principle, we are setting up our inclusion/exclusion criteria to be able to get PVRs kind of in the mid-700s. I think what you've seen in some modern studies that have been done with various products, including with imatinib, by Alexander Rothman in his study, is that you're getting, even in that study where most people were on the equivalent of 200 mg, which would be the lower dose of imatinib, there was a 24% reduction in TPR.
I know there's a lot said about, "W ell, don't you need a 1,000 dyne baseline?" I don't think that's the case. We don't believe that you do. Will we be really happy if we meet those clinical thresholds that are in the market? Yes, there have been lots of drugs approved on data like that. Do we have kind of high expectations and hopes for the drug and for the company that we can be more in that 30-ish range? We do. I think anything in the 20% reduction and 20-meter improvement would tell us that we have a fantastic product.
Okay. Just to be clear, what's clinically meaningful is 20/20, essentially. Y ou guys feel good based off of the IMPRES data and the MOA, they could get to 30% PVR or 30/30.
Yeah, those are our hopes and our expectations. That's right.
Okay. When you guys disclose the PVR data in 2028, would we also get a look at six-minute walk at that time?
Yeah, we will have that data. It's not powered for that, so it's about half the size. The trial's about half the size as the Part B of the study. W e will certainly have that information, and we expect to share that with everyone.
Okay. Can you comment on just the interpretability of that data, and also the fact that six-minute walk for placebo typically is quite noisy? How are you going to manage some of that in the phase III?
Yeah. L ook, the way that it's managed in the phase III is certainly to increase the N in the study. I think 340 patients versus 140 is what we have decided at this point is what we're targeting for Part B for the six-minute walk. We certainly can take a look at Part A, and should we need a bigger sample size, we can do that as well. That's one of the benefits of breaking the study into two pieces. I think fundamentally what we expect to be able to see is some trends. I think it'd be hard for us to think that we could get statistical significance with a smaller number of patients. We're certainly hoping and excited to see that data when it comes.
Sure. Okay. You mentioned earlier, IKT's MOA. It's a prodrug, and you should get good efficacy. Talk about the safety component as well, because that was sort of an issue with IMPRES.
Yeah, it's a great point. There were a lot of patients that discontinued because of really meaningful GI side effects. Sometimes I think we say that and you think, "I t's just a little bit of a stomach ache or maybe some nausea." This is debilitating nausea, vomiting. This is patients on imatinib not being able to leave the house, and more importantly, not being able to tolerate the 400 mg dose. There's a couple of things here. We designed a prodrug that stays intact. There's some real benefits of that. C-KIT in the GI tract, as you could think of it almost as one of the most important pacemakers of the GI system.
If you're inhibiting that, you're slowing down gastric emptying, you're causing a lot of nausea and vomiting. We've shown pre-clinically that we have a meaningfully different profile than imatinib does. In fact, imatinib looks a lot like morphine. I don't have to educate anyone on the effects of morphine on the GI tract and nausea and vomiting. We are seeing a very clean profile right now in the preclinical studies. We have also done something else, which is we are doing a slow titration to get from our lower dose to the higher dose. In IMPRES, they move people from 200 mg to 400 mg, so from the low dose to the high dose in two weeks.
We think that caused a lot of issues. When you talk to the investigators that were part of that study, they would say that is one of the number one things that really caused issues for dropouts. Not only do we have what we would call kind of a GI protective prodrug here for imatinib, but we are also going to take eight weeks to get them to the high dose.
Okay.
We have got a 300 mg dose, a 400 mg dose, and a 500 mg dose. You can think of our 300 mg as being a little bit better than 200 mg, or a little more drug, I should say. Our 500 mg dose is right around 383 mg, so close to that 400 mg. I think the combination of those two things has us very optimistic that we are going to be able to get more people to the higher dose. The efficacy and the adverse events are certainly dose-related with imatinib.
Okay. What is your level of confidence to get these patients up to the 500 mg dose? Is it kind of like a forced titration, or is it kind of like PK dependent? Maybe you guys will do some PK sampling and things like that. How should we think about patients reaching the target dose to get maximum efficacy?
Yeah. I t's really up to the individual investigator, and of course, the patient, but we are encouraging all patients to go through the doses. Certainly, if somehow they can't tolerate it, we're not going to overly force people to get there. If they get to the 500 mg dose and for some reason they can't tolerate it, they're allowed to step down. This is all part of the procedures that we put in place so that we can keep people in the trial. We think the real key here is the design elements to make sure that we're not ending up with dropouts like they did in IMPRES, but rather we can find the right and maximum dose for each patient.
And maybe it's a good time to just point out that even the lower doses of imatinib have been shown multiple times to deliver 20% reductions in PVR and 20-meter improvements in six-minute walks. So, while I'm expressing our desire to get to the higher doses, because I think that will deliver class-leading efficacy that would look similar to what sotatercept's shown, there's certainly the lower doses that would make a great product for the vast majority of patients.
Okay. In terms of safety, I guess given the prodrug and the novel formulation here, what do you expect to see in terms of nausea, vomiting, and GI distress?
Yeah. Look, I think we've shown pre-clinically that we have a much, much lower effect on that. Now we have to conduct a clinical study here to see if that bears out in patients, but we're feeling pretty good about that. When it is converted to imatinib, because you're asking about safety, we're going to see those same kind of systemic side effects that you see with imatinib. So, edema and some other issues. D octors, especially investigators in a clinical trial, are well-versed on how to handle edema. Practicing doctors are, and for sure the investigators are.
Yeah. I think that's a really important point around edema. Because I believe when IMPRES was run, some of the investigators categorized edema as worsening of disease when it was in fact kind of on target. What you're saying is the doctors, the investigators that are part of your trial, they've kind of caught up with literature, with how the MOA works, so that there wouldn't be some of this mischaracterization of edema.
That's a great way to say it, Dennis. That trial ran to conclusion, and it was really the missing data and the dropouts that caused so much of the problems for Novartis to be able to get that drug approved. I feel like we're really in a great place to be able to keep patients in the trial. That last point you made is spot on. Some of that edema was seen as a clinical worsening event.
We're going to great lengths to make sure that there's multiple classifications of what a clinical worsening event would have to be, not just the fact that someone got some edema. Of course, all throughout the protocol investigator training, we've been crystal clear about how that edema should be managed and really what the definition of a clinical worsening event will be. We feel like we've learned a lot, and in addition, the medical community investigators have caught up with the best way to evaluate that.
Sure. Right now you guys are focused in PAH, but talk about the opportunities outside of PAH.
Yeah. Pu t very simply, this antiproliferative mechanism of action could be very valuable in group two, could be very valuable in group three perhaps as well. We're excited about those opportunities. We're going to do some preclinical studies to see if the mechanism makes sense. We're going to be doing that during 2027. You asked earlier about what are data readouts. What we're trying to do, we understand that these trials take a lot of time. We have the safety readout, then the Part A, then the Part B. We released some preclinical data in combination with sotatercept this year. I think that was well received by the market because we're always asked that question, "Can you use it with sotatercept?" I think we're showing that we can.
There have been three or four studies now that have shown a kinase inhibitor with sotatercept provides additive or synergistic effect. Then hopefully next year we'll also produce some preclinical data that shows that the mechanism may be appropriate for group two or group three.
Sure. One of your PAH competitors filed an NDA on sort of a mixed phase III. The FDA is supposed to accept the NDA in November?
Yeah.
What are you looking for in that update? What are you looking for in that whole regulatory review process, so that you could apply it to your own future?
Yeah, it's a great question. Look, we're always rooting for other companies, and we're rooting for patients and doctors for sure. I think in some ways you could think of it as a win-win. If it gets accepted and it's reviewed, and even if it's approved on that dataset, you have to come to the conclusion that the FDA has kind of widened the confidence interval for the set of data that is approvable. People can argue a lot about whether it will be or it won't be. I think that's not for us to say. I f it was approved on that dataset, I think that, s ome echo, I think that would be a good thing for us.
In the spirit of win-win, if it wasn't accepted or it wasn't approved, well, then that would clearly put us in the number two position to get out there. I feel like we have a chance to produce a clinical profile that is really overall maybe as good or even better than sotatercept. Not only do we think we'll be able to maintain the efficacy levels of imatinib, because again, it just converted right into free imatinib, maybe in many ways improve on the safety and tolerability profile, or at least the way it's perceived and managed. I n addition to that, we have an oral once a day, and that is a huge clinical utility benefit.
We know from the typical prescribing physician now, like we talk a lot about investigators and thought leaders, but the majority of the prescriptions written are the average PAH center or treating physician, and the idea to have an oral once a day is a huge benefit.
Yeah. Maybe talk about, once you guys get approved, the commercial positioning of your product, where would you most likely focus in terms of the initial targeted outreach?
Yeah, look, I think initially with all of these products, they get tried in the more severe patients. We saw that with sotatercept. You see it with almost all new mechanisms of action. What's been really encouraging, but it shows you how much of an unmet need is out there, as you're already seeing sotatercept be used in more moderate patients, and you're hearing doctors talk about that. When we show doctors the profile of our product, I think we have a chance to be used even earlier than they are because it's oral once a day, and we do expect to have kind of a clinical profile that matches them, and maybe even from a safety standpoint, a product that has an even better profile.
L ook, over the long term, as I said in the beginning, I think we believe that a product like ours could be that second product that you're put on. Maybe it's a PDE5 and an ERA, and as soon as you need something more, the doctors are going to want an antiproliferative, and an oral once-a-day antiproliferative with great efficacy and tolerability is a terrific choice for them. I think in the longer term than that, maybe five years, six years, seven years, you may see doctors in difficult-to-treat patients just add an antiproliferative right to their starting regimen.
Okay. Maybe in the last couple minutes, just remind us how much cash and runway you have, but also importantly, the IP. If you can comment a little bit about that as well.
Yeah, sure. W hat we've said to the market is that we have enough runway to get through the trial. So, think of that as sort of mid-2029 is when we said we'd finish the Part B of the study. The IP is 2039, and then with use patents out to 2044. So, we have a long runway in front of us. It is not just a reformulation of imatinib. It is a new NCE, but we do have the benefit of being able to use the 505(b)(2) strategy. W hen we converted from sort of the sequential phase II-B and then a phase III program, we actually shaved about three years off the time to an NDA or the time to approval. For everybody in the room today, well, that's kind of built in, but that was a huge win a year ago.
Okay. Maybe in the last minute, Mark, any sort of closing remarks to investors as we think about the next 12 - 36 months?
I think for everyone in this room and investors around the world, the team is doing a great job. 28 countries and 79 sites. We are up and running. We are, I think, meeting a huge unmet need in the market to have a second antiproliferative come to the market, one with a great clinical profile. We're really optimistic about what the data could look like. These trials, they take time, and we understand from an investor standpoint, a year away or a year and a half away feels like a lot of time, but we're going to keep delivering data. 2027, we have that safety readout disclosure, and then mid-2028, the PVR data.
That PVR data has been a huge catalyst for almost every company that's produced great data. T hen the pivotal date in 2029. All along the way, we're going to keep producing preclinical data for additional indications. So, we're super excited about the product. Team is doing a great job, and hopefully as we get closer and closer, the market will really appreciate that.
Perfect. T hank you so much, Mark, for being here and-
Thank you, Dennis.
and helping us.
Thank you.